Capital One Initiates Coverage On Protagonist Therapeutics with Overweight Rating

Protagonist Therapeutics, Inc. +1.57%

Protagonist Therapeutics, Inc.

PTGX

59.05

+1.57%

Capital One analyst Tim Chiang initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Overweight rating.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via